Forty Seven, Inc.
Forty Seven, Inc. (FTSV): 3 pipeline candidates · ~44 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
43.9 months
D/E 0.08 · 0% dilution
Lead: Phase 1
3 candidates
N/A
N/A
A transparent, data-derived signal for Forty Seven, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$213.8M
Quarterly Burn
$22.3M
Runway
43.9 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| fsi-174 | Preclinical |
| fsi-189 | Preclinical |
| magrolimab | Phase 1 |
Frequently asked questions
How many drug candidates are in Forty Seven, Inc.'s pipeline?
Forty Seven, Inc. (FTSV) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Forty Seven, Inc.'s lead drug candidate?
Forty Seven, Inc.'s most advanced tracked candidate is fsi-174 (Preclinical) for stem cell transplantation conditioning.
What is Forty Seven, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Forty Seven, Inc. has approximately 43.9 months of cash runway.
Who is the CEO of Forty Seven, Inc.?
Genentech Inc is the chief executive officer of Forty Seven, Inc. (FTSV).
Get the full picture on Forty Seven, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.